Application 021137
- Type
- NDA
- Sponsor
- GENUS LIFESCIENCES
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.025MG | No | No |
| 002 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.05MG | No | No |
| 003 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.075MG | No | No |
| 004 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.088MG | No | No |
| 005 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.1MG | No | No |
| 006 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.112MG | No | No |
| 007 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.125MG | No | No |
| 008 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.137MG | No | No |
| 009 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.15MG | No | No |
| 010 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.175MG | No | No |
| 011 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.2MG | No | No |
| 012 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.3MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021137-001 | LEVOLET | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-002 | LEVOLET | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-003 | LEVOLET | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-004 | LEVOLET | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-005 | LEVOLET | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-006 | LEVOLET | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-007 | LEVOLET | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-008 | LEVOLET | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-009 | LEVOLET | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-010 | LEVOLET | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-011 | LEVOLET | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-012 | LEVOLET | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021137-001 | AB1 |
| N021137-001 | AB2 |
| N021137-001 | AB3 |
| N021137-001 | AB4 |
| N021137-002 | AB1 |
| N021137-002 | AB2 |
| N021137-002 | AB3 |
| N021137-002 | AB4 |
| N021137-003 | AB1 |
| N021137-003 | AB2 |
| N021137-003 | AB3 |
| N021137-003 | AB4 |
| N021137-004 | AB1 |
| N021137-004 | AB2 |
| N021137-004 | AB3 |
| N021137-004 | AB4 |
| N021137-005 | AB1 |
| N021137-005 | AB2 |
| N021137-005 | AB3 |
| N021137-005 | AB4 |
| N021137-006 | AB1 |
| N021137-006 | AB2 |
| N021137-006 | AB3 |
| N021137-006 | AB4 |
| N021137-007 | AB1 |
| N021137-007 | AB2 |
| N021137-007 | AB3 |
| N021137-007 | AB4 |
| N021137-008 | AB1 |
| N021137-008 | AB2 |
| N021137-008 | AB3 |
| N021137-008 | AB4 |
| N021137-009 | AB1 |
| N021137-009 | AB2 |
| N021137-009 | AB3 |
| N021137-009 | AB4 |
| N021137-010 | AB1 |
| N021137-010 | AB2 |
| N021137-010 | AB3 |
| N021137-010 | AB4 |
| N021137-011 | AB1 |
| N021137-011 | AB2 |
| N021137-011 | AB3 |
| N021137-011 | AB4 |
| N021137-012 | AB1 |
| N021137-012 | AB2 |
| N021137-012 | AB3 |
| N021137-012 | AB4 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB4 | 4 | 84e616aacf4f… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Amneal Pharmaceuticals NY LLC | fca88c97-5cd4-4834-ba87-deb5bd637788 | 2024-12-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 2646a481-09a5-af6a-e063-6394a90a16da | 2024-11-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 924bb6e9-4b2b-406f-a0a8-376b1f22f1f5 | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCarePharmaceuticals, Inc. | 2380859a-5b65-f88f-e063-6394a90aa4e2 | 2024-10-02 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | b4f8dfd0-b15a-4da5-a0d0-ad768e0b7ff8 | 2024-09-01 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8f83fd60-5aa7-4e7f-a6e9-917e2c1abf27 | 2024-08-21 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | d79526e0-d327-4545-a50c-99678766d817 | 2024-08-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | c22af2e0-fb36-4645-a911-3d293af5bd88 | 2024-08-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | b1b8c5a4-8132-24d2-e053-2995a90a59ec | 2024-07-17 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Aurobindo Pharma Limited | c760d0cc-2245-4914-8c67-d536c41ac90f | 2024-07-17 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | cba6bb77-2140-6cba-e053-2995a90aa1b6 | 2024-07-14 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Hikma Pharmaceuticals USA Inc. | 6279390b-ee61-4ef9-ac15-25537ca783c1 | 2024-07-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | a2157cf0-5c8f-7e69-e053-2a95a90aa083 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | a215da96-acd9-6b8d-e053-2995a90a7e0d | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCar Pharmaceuticals,Inc. | a2194c58-b755-e6b5-e053-2a95a90a36d4 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | 1ac856d1-7067-a71d-e063-6294a90acc7c | 2024-06-13 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 56c633a9-3f64-46bd-b93f-afbff92b5559 | 2024-06-03 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | Teva Pharmaceuticals, Inc. | 60cadfd7-82b5-4207-97e1-1dd0655efb27 | 2024-06-01 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | DIRECT RX | a5f15022-1166-09fe-e053-2a95a90aa218 | 2024-05-23 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8849620a-5e8d-4031-884f-9a2817b050f2 | 2024-05-02 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.